- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AURA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | Aura Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 01.06. | Aura Biosciences schließt Patientenrekrutierung für Phase-3-Studie zu Augenkrebs-Medikament ab | 2 | Investing.com Deutsch | ||
| 19.05. | Aura Biosciences, Inc.: Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 19.05. | Aura Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.05. | Aura Biosciences, Inc.: Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights | 431 | GlobeNewswire (Europe) | Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened... ► Artikel lesen | |
| 11.05. | Aura Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Aura Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.05. | Aura Biosciences schließt Kapitalerhöhung über 299,4 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 05.05. | Aura Biosciences closes $299.4 million public offering | 2 | Investing.com | ||
| 05.05. | Aura Biosciences, Inc.: Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 98 | GlobeNewswire (Europe) | BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve... ► Artikel lesen | |
| 04.05. | Aura Biosciences platziert Aktienpaket im Wert von 260,3 Mio. US-Dollar zu 6 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
| 04.05. | Aura Biosciences prices $260M stock, warrant offering | 1 | Seeking Alpha | ||
| 04.05. | Aura Biosciences prices $260.3M stock offering at $6/share | 4 | Investing.com | ||
| 04.05. | Aura Biosciences launches public offering of common stock | 1 | Investing.com | ||
| 04.05. | Aura Biosciences names Natalie Holles as CEO | 2 | Seeking Alpha | ||
| 04.05. | Aura Biosciences kündigt öffentliches Aktienangebot an | 2 | Investing.com Deutsch | ||
| 04.05. | Aura Biosciences names Natalie Holles as new CEO | 1 | Investing.com | ||
| 04.05. | Aura Biosciences, Inc.: Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion | 225 | GlobeNewswire (Europe) | Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors... ► Artikel lesen | |
| 04.05. | Aura Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | H.C. Wainwright reiterates Aura Biosciences stock rating at buy | 6 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,45 | +0,26 % | Biontech setzt weiter auf mRNA | Mainz - Biontech will weiter auf mRNA-Technologie setzen. Das berichtet das "Handelsblatt" unter Berufung auf mehrere mit der Sache vertraute Personen.Nach dem Weggang der Gründer hat das Mainzer Biotech-Unternehmen... ► Artikel lesen | |
| EVOTEC | 4,884 | +2,43 % | Evotec nach dem Absturz: Droht noch mehr Druck auf die Aktie? | Die Aktie von Evotec bleibt nach den jüngsten Geschäftszahlen unter Druck. Zwar wächst das operative Geschäft weiter, doch sinkende Gewinne und hohe Investitionen sorgen für Verunsicherung bei Anlegern.... ► Artikel lesen | |
| VALNEVA | 2,312 | +1,09 % | EXKLUSIV zu Valneva: Was große Adressen heute bereits wissen - Meine Analyse im Detail | ||
| AMGEN | 303,60 | -1,09 % | Amgen loses in Harbour antibody patent case, ordered to pay $20M+ | ||
| NOVAVAX | 7,860 | +2,61 % | Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade | ||
| BIOGEN | 170,58 | -1,31 % | Lilly, Biogen, Eisai and Genentech sponsor new 'Let's Talk Alzheimer's' podcast | ||
| PALATIN TECHNOLOGIES | 12,690 | -8,84 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 526,40 | -0,45 % | Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy | ||
| VIVOSIM LABS | 1,200 | +5,26 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,400 | +2,21 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,780 | +12,62 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 45,000 | +8,89 % | Tempus AI study validates heart rhythm prediction software | ||
| BIOCRYST PHARMACEUTICALS | 7,650 | +1,57 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 47,560 | -1,65 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen |
Das Unternehmen AURA BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,47 % bei einem Aktienkurs von 6,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AURA BIOSCIENCES INC finden Sie auf Wallstreet Online.